The appointment of Gavin MacBeath as CEO and board member of TScan Therapeutics is a significant event for the company. However, the short-term impact on TCRX stock price is neutral as the market has likely already priced in his acting CEO role since March 2023. The change in his role from Chief Scientific and Operating Officer to CEO may not have a significant immediate impact on the company's operations or stock price.